文献速递艾滋病与性传播感染

英国HIV感染者对在诊所和社区环境中实施长效卡博特韦联合利匹韦林注射的视角:来自反性别歧视、反种族歧视、反年龄歧视实施长效新型抗逆转录病毒药物研究的结果

Perspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该研究于2022年5月至12月在英国6个站点开展,评估在诊所和社区环境中提供每2个月一次卡博特韦联合利匹韦林(CAB+RPV)注射的可行性、可接受性和适当性。114名参与者中27人选择社区注射,12个月时注射本身的可行性、可接受性和适当性评分较高(79.0-87.4%),而社区环境评分较低(44.2-47.4%);选择社区注射者对社区环境的评分较高(73.1-80.8%)。结论认为CAB+RPV注射高度可行、可接受和适当,但选择社区注射者较少,需进一步探索未提供的替代社区场所。

要点

  • 12个月时注射本身的可行性、可接受性和适当性评分较高(79.0-87.4%),社区环境评分较低(44.2-47.4%)。
  • 114名参与者中27人选择社区注射,该亚组对社区环境的评分较高(73.1-80.8%)。
  • 对污名、不便和失去信任临床医生的担忧负面影响对社区注射的看法。

核心结论

  • CAB+RPV注射被认为高度可行、可接受和适当,但选择社区注射者较少。
  • 选择社区注射者认为社区注射高度可接受和可行。
  • 作者认为需进一步探索未提供的替代社区场所(如初级保健、药房)中CAB+RPV的提供。

研究设计与样本

  • 实施研究于2022年5月至12月在英国6个站点开展,要求包容性招募。
  • 注射在诊所提供(第1-6个月),第6-12个月根据患者选择在诊所或社区环境提供。
  • 共114名参与者,54%为女性,70%为种族少数群体,40%年龄≥50岁。
  • 在基线、第4个月和第12个月使用可行性(FIM)、可接受性(AIM)和适当性(IAM)验证量表进行调查;14名参与者在基线和第12个月完成访谈。
  • 主要终点:第12个月同意注射和社区环境可行的参与者比例(FIM≥4)。

主要发现

  • 站点提供的社区环境包括:家庭访视(n=3)、HIV支持组织(n=2)和社区诊所(n=1)。
  • 114名参与者中27人选择在社区环境接受注射。
  • 第12个月总体FIM/AIM/IAM评分对注射为79.0-87.4%,对社区环境为44.2-47.4%。
  • 亚组分析提示评分按性别和种族存在差异。
  • 在参加社区注射者中,第12个月对社区环境的FIM/AIM/IAM评分较高(73.1-80.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需进一步探索未提供的替代社区场所(如初级保健、药房)中CAB+RPV的提供。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The equity-focused Implementing Long-Acting Novel Antiretrovirals study evaluated feasibility, acceptability, appropriateness of delivering on-label 2-monthly cabotegravir and rilpivirine (CAB + RPV) injections for human immunodeficiency virus (HIV)-1 therapy in clinics and community settings. METHODS: The study, which mandated inclusive recruitment, was conducted May-December 2022 at 6 UK sites. Injections were delivered in clinic (month [M] 1-6) and in clinic or community setting according to patient choice (M6-12). Surveys were completed at baseline, M4, and M12 using validated measures for feasibility (FIM), acceptability (AIM), and appropriateness (IAM). Primary endpoint: proportion of participants agreeing that the injection and community setting were feasible (FIM ≥4) at M12. Fourteen participants completed interviews at baseline and M12. RESULTS: Community settings offered by sites included: home visits (n = 3), HIV support organizations (n = 2), and community clinic (n = 1). Of 114 participants, 54% were female, 70% racially minoritized, and 40% aged ≥50 years. A total of 27/114 chose to receive injections in community settings. FIM/AIM/IAM scores at M12 were high for the injection (79.0-87.4%) and lower for the community setting (44.2-47.4%) overall. Subgroup analyses indicated differences in scores by gender and ethnicity. Among those who attended the community, FIM/AIM/IAM scores for the community setting at M12 were high (73.1-80.8%). Concerns about stigma, inconvenience, and losing access to trusted clinicians negatively influenced perceptions of receiving injections at community settings, amongst other factors. CONCLUSIONS: CAB + RPV injections were considered highly feasible, acceptable, and appropriate; however, few chose community delivery. Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB + RPV delivery in alternative community sites not offered (eg, primary care, pharmacies) is warranted. CLINICALTRIALS.GOV: NCT05294159.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Orkin C, Hayes R, Haviland J, et al. Perspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study. Clin Infect Dis. 2025. PMID: 39465685. doi:10.1093/cid/ciae523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。